Acquiring Company
Ensysce Biosciences
Acquired Company
Cy Biopharma
La JollaManufacturingBiotechnologyHealthcareHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Former Cy shareholders will hold approximately 75% of the combined entity, effectively integrating Cy's pipeline into Ensysce.
Quick answer
Ensysce Biosciences is acquiring Cy Biopharma for $77 million, announced August 7, 2026. Ensysce Biosciences is based in La Jolla, California, United States.
- How much did Ensysce Biosciences pay for Cy Biopharma?
- The reported deal value is $77 million.
- What does Ensysce Biosciences do?
- Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription..
- Where are Ensysce Biosciences and Cy Biopharma based?
- Ensysce Biosciences is based in La Jolla, California, United States.
- Who are the decision-makers at Ensysce Biosciences?
- Fundz holds 1 contact at Ensysce Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Hardware
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Enova to acquire Grasshopper Bank for expansion (July 12, 2026)
- eFinance to acquire Tamweely Financial Services (August 13, 2026)
- Hope Bancorp to acquire SMBC MANUBANK unit (July 28, 2026)
- Capital One merges with Discover Financial Services (July 12, 2026)
- J.C. Flowers to acquire Republic Finance (June 26, 2026)
- Maybank acquires Maybank Ageas (September 11, 2026)
Who to call at Ensysce Biosciences, and when
When Ensysce Biosciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ensysce Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ensysce Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ensysce Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ensysce Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cy Biopharma?
Cy Biopharma was acquired by Ensysce Biosciences, based in La Jolla. The deal was reported on August 7, 2026. Ensysce Biosciences, Inc. Ensysce Biosciences is publicly traded (ENSC) and operates in Manufacturing.
When did Ensysce Biosciences acquire Cy Biopharma?
Ensysce Biosciences's acquisition of Cy Biopharma was reported on August 7, 2026. Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cy Biopharma do?
Cy Biopharma is a biopharmaceutical firm developing therapies for pain conditions. They focus on neuroplastogenic approaches to treat chronic pain syndromes. Their lead asset is a neuroplastogenic receptor agonist for complex regional pain syndrome. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.